START Midwest’s ST101 (Sapience) clinical trial was recently featured on the website BioSpace, an online hub for Life Sciences news. The Phase I/II study is currently researching the use of ST-101, a peptide therapy, in adult patients with unresectable and metastatic solid tumors. START Midwest’s Nehal Lakhani, MD, PhD, told BioSpace, “We are eager to explore the profile of ST101 and to investigate the role of C/EBPβ inhibition for the treatment of advanced solid tumors. We are always looking for opportunities to accelerate the development of new treatments to improve patients’ lives and give them hope against cancer, and ST101 holds that potential.” Read the full article here.
START Midwest, located at CHCWM’s East facility, is part of START’s global network of Phase I clinical research sites. It is the largest Phase I oncology drug development program in Michigan and one of the largest in the Midwest. It offers cancer patients access to cutting-edge clinical trial drugs, including immunotherapy and targeted therapy options.
Becky Downing, Social Media & Marketing Specialist